<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04663217</url>
  </required_header>
  <id_info>
    <org_study_id>AZ 11716</org_study_id>
    <nct_id>NCT04663217</nct_id>
  </id_info>
  <brief_title>Exercise Hemodynamic, Right Ventricular Coupling and Echocardiography in Pulmonary Hypertension</brief_title>
  <acronym>EXERTION</acronym>
  <official_title>Exercise Hemodynamic, Right Ventricular Coupling and Echocardiography in Pulmonary Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Giessen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Giessen</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to investigate the exercise profile in pulmonary hypertension patients with&#xD;
      either pulmonary arterial hypertension, chronic thromboembolic pulmonary hypertension or&#xD;
      pulmonary hypertension due to left heart disease and in disease control.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a dual-center observational prospective study in patients with pulmonary arterial&#xD;
      hypertension, chronic thromboembolic pulmonary hypertension, pulmonary hypertension due to&#xD;
      left heart disease. Patients undergoing right heart catheterisation due to dyspnoe with&#xD;
      invasive exclusion of pulmonary hypertension will be recruited as disease control.&#xD;
&#xD;
      The study comprises a 1-day screening period, followed by a right heart catheterization with&#xD;
      exercise challenge.&#xD;
&#xD;
      The study starts with screening, information of the patients and Informed Consent Form&#xD;
      signature at day -1. Screening and inclusion of the patient can be performed on the same day.&#xD;
      On the day of the planned right heart catheterization based on clinical grounds, exercise&#xD;
      right heart catheterisation (RHC) using Swan-Ganz and/or Conductance catheters with&#xD;
      simultaneous echocardiography will be performed. End of study is defined as a complete&#xD;
      exercise RHC. Adverse events will be assessed until 1 day after the exercise RHC.&#xD;
&#xD;
      After placement of the Swan-ganz or Conductance catheter patients will undergo an exercise&#xD;
      challenge using the following protocol in semi-supine position until exhaustion:&#xD;
&#xD;
        -  Incremental workload increase of 20Watt every 2-4 min.&#xD;
&#xD;
        -  For patients not able to start a 20 Watt, initial workload can be adjusted to a minimum&#xD;
           of 5 Watt with 5 Watt increase every 2-4 min until exhaustion&#xD;
&#xD;
        -  Maximal exercise duration is 10-12 minutes&#xD;
&#xD;
        -  Symptoms of dyspnoea during exercise will be rated by subjects at baseline, after 6&#xD;
           minutes and at maximum according to the Borg perceived dyspnoea (0-10) scale.&#xD;
&#xD;
      Simultaneously, echocardiography and lung ultrasound will be performed before exercise&#xD;
      (baseline), after 6 minutes of exercise and at maximum.&#xD;
&#xD;
      After assessment of right ventriclure pressure-volume loops during maximum exercise, guided&#xD;
      by echocardiographic the conductance catheter will be placed in the right atrium to obtain&#xD;
      right atrium pressure-volume loops during maximum exercise.&#xD;
&#xD;
      Optional, the exercise RHC will be performed without the Conductance catheter and only with&#xD;
      the Swan-Ganz catheter. In this case, pressure values and cardiac output will be measured&#xD;
      using the thermodilution method, averaging 3-5 measurements at baseline, 6 minutes and&#xD;
      maximum. Detailed assessment of right atrial pressure curves (with a and v wave) will be&#xD;
      performed at baseline, 6 minutes and maximum exercise.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2020</start_date>
  <completion_date type="Anticipated">November 4, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 4, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Day</target_duration>
  <primary_outcome>
    <measure>exercise pulmonary arterial pressure</measure>
    <time_frame>1 day</time_frame>
    <description>mean pulmonary arterial pressure (mmHg)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>exercise cardiac output</measure>
    <time_frame>1 day</time_frame>
    <description>cardiac output (l/min);</description>
  </primary_outcome>
  <primary_outcome>
    <measure>exercise pulmonary wedge pressure</measure>
    <time_frame>1 day</time_frame>
    <description>pulmonary arterial wedge pressure (mmHg)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>exercise arterial elastance</measure>
    <time_frame>1 day</time_frame>
    <description>arterial elastance (mmHg/mL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>exercise end-systolic elastance</measure>
    <time_frame>1 day</time_frame>
    <description>end-systolic elastance (mmHg/mL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>exercise mean right atrial pressure</measure>
    <time_frame>1 day</time_frame>
    <description>mean right atrial pressure (mmHg)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>exercise right atrial function</measure>
    <time_frame>1 day</time_frame>
    <description>right atrial strain (%)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>exercise right volume</measure>
    <time_frame>1 day</time_frame>
    <description>right ventricular volume (ml)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>exercise right ventriculare function</measure>
    <time_frame>1 day</time_frame>
    <description>right ventricular strain (%)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>exercise right atrial volume-pressure curves</measure>
    <time_frame>1 day</time_frame>
    <description>atrial volume to pressure ratio (ml/mmHg)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>exercise lung congestion</measure>
    <time_frame>1 day</time_frame>
    <description>B-Lines</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>exercise left atrial function</measure>
    <time_frame>1 day</time_frame>
    <description>left atrial strain (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>exercise left atrial volume</measure>
    <time_frame>1 day</time_frame>
    <description>left atrial volume (ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>exercise hepatic backflow</measure>
    <time_frame>1 day</time_frame>
    <description>diameter inferior vena cava (mm)</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Hypertension, Pulmonary</condition>
  <condition>Hypertension, Pulmonary Arterial</condition>
  <arm_group>
    <arm_group_label>Pulmonary arterial hypertension</arm_group_label>
    <description>Patients with mean pulmonary arterial pressure above 25 mmHg, and a pulmonary capillary wedge pressure below 15 mmHg classified into group 1 of the clinical classification of pulmonary hypertension.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pulmonary hypertension due to left heart disease</arm_group_label>
    <description>Patients with mean pulmonary arterial pressure above 25 mmHg, and a pulmonary capillary wedge pressure above 15 mmHg with left heart disease, classified into group 2 of the clinical classification of pulmonary hypertension.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chronic thromboembolic pulmonary hypertension</arm_group_label>
    <description>Patients with mean pulmonary arterial pressure above 25 mmHg, and a pulmonary capillary wedge pressure below 15 mmHg with a history of pulmonary embolism, classified into group 4 of the clinical classification of pulmonary hypertension.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Patients with mean pulmonary arterial pressure below 25 mmHg, and a pulmonary capillary wedge pressure below 15 mmHg with exclusion of pulmonary hypertension.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Exercise</intervention_name>
    <description>After placement of the right heart catheter patients will undergo an exercise challenge in semi-supine position until exhaustion</description>
    <arm_group_label>Chronic thromboembolic pulmonary hypertension</arm_group_label>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Pulmonary arterial hypertension</arm_group_label>
    <arm_group_label>Pulmonary hypertension due to left heart disease</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Confirmed diagnosis of either pulmonary arterial hypertension; pulmonary hypertension due&#xD;
        to left heat disease; chronic thromboembolic pulmonary hypertension; or invasive exclusion&#xD;
        of pulmonary hypertension (control group)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed diagnosis of pulmonary arterial hypertension (World Health Organization&#xD;
             group 1)&#xD;
&#xD;
          -  Pulmonary hypertension due to left heart disease (World Health Organization group 2)&#xD;
&#xD;
          -  Chronic thromboembolic pulmonary hypertension (World Health Organization group 4)&#xD;
&#xD;
          -  Invasive exclusion of pulmonary hypertension&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Planned right heart catheterization based on clinical grounds&#xD;
&#xD;
          -  Stable specific PAH medications&#xD;
&#xD;
          -  Ability to undergo cycle ergometry&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other etiologic groups of pulmonary hypertension (World Health Organization group 3,&#xD;
             5)&#xD;
&#xD;
          -  Unstable or severe coronary artery disease&#xD;
&#xD;
          -  Uncontrolled arterial hypertension&#xD;
&#xD;
          -  Left ventricular ejection fraction &lt; 30%&#xD;
&#xD;
          -  Severe congenital or acquired valvular or myocardial disease&#xD;
&#xD;
          -  Progressive left heart failure&#xD;
&#xD;
          -  History of severe ventricular arrhythmias&#xD;
&#xD;
          -  Severe, terminal renal impairment&#xD;
&#xD;
          -  Severe obstructive or restrictive lung disease&#xD;
&#xD;
          -  Severe lung emphysema or interstitial lung disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richter J Manuel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UKGM Giessen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Richter J Manuel, MD</last_name>
    <phone>+4964198556022</phone>
    <email>manuel.j.richter@innere.med.uni-giessen.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kerckhoff-Klinik</name>
      <address>
        <city>Bad Nauheim</city>
        <state>Hesse</state>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richter J Manuel, MD</last_name>
      <phone>+4964198556022</phone>
      <email>manuel.j.richter@innere.med.uni-giessen.de</email>
    </contact>
    <investigator>
      <last_name>Rieth Andreas, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Giessen</name>
      <address>
        <city>Gießen</city>
        <state>Hesse</state>
        <zip>35390</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuel Richter, MD</last_name>
      <phone>+4964198556022</phone>
      <email>manuel.j.richter@innere.med.uni-giessen.de</email>
    </contact>
    <investigator>
      <last_name>Khodr Tello, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 5, 2020</study_first_submitted>
  <study_first_submitted_qc>December 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2020</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>exercise</keyword>
  <keyword>Hypertension, Pulmonary</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Pulmonary Arterial Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Data will be shared upon request.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

